Our data indicate that Apigenin may overcome RAIU reduction by TGF-β at the invasive fronts of thyroid cancer, in particular when Apigenin is administered in combination with PI3Ki, MEKi, or Hsp90i to further increase RAIU. This evidence concerns the gene TGFB1 and thyroid cancer.